What Amgen (AMGN)'s Tezspire Trial Win Means For Shareholders
What Amgen (AMGN)'s Tezspire Trial Win Means For Shareholders Simply Wall Street
Covered in this story
Analyst targets on Amgen
- BMO Capital Markets: $418 → $415 by Oct 2027 via GuruFocus
- Wells Fargo: $415 → $430 by Oct 2027 · Equal-Weight via GuruFocus
- UBS: $415 → $470 by Oct 2027 · Buy via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 6 Oct 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.